$TCBP News clips "We are extremely pleased to receive such positive data from our phase 1b/2a study demonstrating OmnImmune® as safe and tolerable among patients with advanced acute Myeloid Leukemia," said Bryan Kobel, Chief Executive Officer of TC BioPharm. "These results underline OnmImmune's potential in becoming a viable AML treatment. We look forward to reporting additional phase 2/3 clinical data during the first half of 2022."